{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:53:29Z","timestamp":1760550809353,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00125-019-4861-x","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T21:29:17Z","timestamp":1554240557000},"page":"900-904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation"],"prefix":"10.1007","volume":"62","author":[{"given":"Matilde","family":"Monteiro-Soares","sequence":"first","affiliation":[]},{"given":"In\u00eas","family":"Ribeiro-Vaz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3695-192X","authenticated-orcid":false,"given":"Edward J.","family":"Boyko","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"issue":"5","key":"4861_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2337\/diacare.13.5.513","volume":"13","author":"RE Pecoraro","year":"1990","unstructured":"Pecoraro RE, Reiber GE, Burgess EM (1990) Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 13(5):513\u2013521. \n                    https:\/\/doi.org\/10.2337\/diacare.13.5.513","journal-title":"Diabetes Care"},{"issue":"4","key":"4861_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2337\/dc17-2210","volume":"41","author":"EJ Boyko","year":"2018","unstructured":"Boyko EJ, Seelig AD, Ahroni JH (2018) Limb- and person-level risk factors for lower-limb amputation in the prospective Seattle Diabetic Foot Study. Diabetes Care 41(4):891\u2013898. \n                    https:\/\/doi.org\/10.2337\/dc17-2210","journal-title":"Diabetes Care"},{"issue":"2","key":"4861_CR3","doi-asserted-by":"publisher","first-page":"22S","DOI":"10.1016\/j.jvs.2015.10.005","volume":"63","author":"R Hasan","year":"2016","unstructured":"Hasan R, Firwana B, Elraiyah T et al (2016) A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. J Vasc Surg 63(2):22S\u201328S. \n                    https:\/\/doi.org\/10.1016\/j.jvs.2015.10.005","journal-title":"J Vasc Surg"},{"issue":"4","key":"4861_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/1534734617737660","volume":"16","author":"J-L Kim","year":"2017","unstructured":"Kim J-L, Shin JY, Roh S-G, Chang SC, Lee N-H (2017) Predictive laboratory findings of lower extremity amputation in diabetic patients: meta-analysis. Int J Low Extrem Wounds 16(4):260\u2013268. \n                    https:\/\/doi.org\/10.1177\/1534734617737660","journal-title":"Int J Low Extrem Wounds"},{"issue":"12","key":"4861_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.bjps.2017.07.015","volume":"70","author":"JY Shin","year":"2017","unstructured":"Shin JY, Roh SG, Sharaf B, Lee NH (2017) Risk of major limb amputation in diabetic foot ulcer and accompanying disease: a meta-analysis. J Plast Reconstr Aesthet Surg 70(12):1681\u20131688. \n                    https:\/\/doi.org\/10.1016\/j.bjps.2017.07.015","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"3","key":"4861_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1534734614545872","volume":"13","author":"ZQ Tang","year":"2014","unstructured":"Tang ZQ, Chen HL, Zhao FF (2014) Gender differences of lower extremity amputation risk in patients with diabetic foot: a meta-analysis. Int J Low Extrem Wounds 13(3):197\u2013204. \n                    https:\/\/doi.org\/10.1177\/1534734614545872","journal-title":"Int J Low Extrem Wounds"},{"issue":"2","key":"4861_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1464-5491.2010.03192.x","volume":"28","author":"P Battum van","year":"2011","unstructured":"van Battum P, Schaper N, Prompers L et al (2011) Differences in minor amputation rate in diabetic foot disease throughout Europe are in part explained by differences in disease severity at presentation. Diabet Med 28(2):199\u2013205. \n                    https:\/\/doi.org\/10.1111\/j.1464-5491.2010.03192.x","journal-title":"Diabet Med"},{"issue":"2","key":"4861_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/1534734615593190","volume":"14","author":"ZY Zhou","year":"2015","unstructured":"Zhou ZY, Liu YK, Chen HL, Yang HL, Liu F (2015) HbA1c and lower extremity amputation risk in patients with diabetes: a meta-analysis. Int J Low Extrem Wounds 14(2):168\u2013177. \n                    https:\/\/doi.org\/10.1177\/1534734615593190","journal-title":"Int J Low Extrem Wounds"},{"issue":"6","key":"4861_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jamcollsurg.2018.09.021","volume":"227","author":"MP Goldman","year":"2018","unstructured":"Goldman MP, Clark CJ, Craven TE et al (2018) Effect of intensive glycemic control on risk of lower extremity amputation. J Am Coll Surg 227(6):596\u2013604. \n                    https:\/\/doi.org\/10.1016\/j.jamcollsurg.2018.09.021","journal-title":"J Am Coll Surg"},{"key":"4861_CR10","doi-asserted-by":"publisher","unstructured":"Matthews DR, Li Q, Perkovic V et al (2019) Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia. \n                    https:\/\/doi.org\/10.1007\/s00125-019-4839-8","DOI":"10.1007\/s00125-019-4839-8"},{"issue":"2","key":"4861_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D et al (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2014a randomized placebo-controlled trial. Am Heart J 166(2):217\u2013223 e11. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2013.05.007","journal-title":"Am Heart J"},{"issue":"3","key":"4861_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/dom.12829","volume":"19","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR et al (2017) Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19(3):387\u2013393. \n                    https:\/\/doi.org\/10.1111\/dom.12829","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"4861_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2337\/dc18-1380","volume":"42","author":"LS Geiss","year":"2019","unstructured":"Geiss LS, Li Y, Hora I, Albright A, Rolka D, Gregg EW (2019) Resurgence of diabetes-related nontraumatic lower-extremity amputation in the young and middle-aged adult US population. Diabetes Care 42(1):50\u201354. \n                    https:\/\/doi.org\/10.2337\/dc18-1380","journal-title":"Diabetes Care"},{"issue":"5","key":"4861_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.diabet.2018.02.001","volume":"44","author":"D Li","year":"2018","unstructured":"Li D, Yang JY, Wang T, Shen S, Tang H (2018) Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Metab 44(5):410\u2013414. \n                    https:\/\/doi.org\/10.1016\/j.diabet.2018.02.001","journal-title":"Diabetes Metab"},{"key":"4861_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","volume":"140","author":"K Radholm","year":"2018","unstructured":"Radholm K, Wu JH, Wong MG et al (2018) Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - a systematic review. Diabetes Res Clin Pract 140:118\u2013128. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2018.03.027","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"4861_CR16","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1111\/dom.13459","volume":"20","author":"S Adimadhyam","year":"2018","unstructured":"Adimadhyam S, Lee TA, Calip GS, Smith Marsh DE, Layden BT, Schumock GT (2018) Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study. Diabetes Obes Metab 20(12):2792\u20132799. \n                    https:\/\/doi.org\/10.1111\/dom.13459","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"4861_CR17","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"PB Ryan","year":"2018","unstructured":"Ryan PB, Buse JB, Schuemie MJ et al (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20(11):2585\u20132597. \n                    https:\/\/doi.org\/10.1111\/dom.13424","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"4861_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/dom.13115","volume":"20","author":"Z Yuan","year":"2018","unstructured":"Yuan Z, DeFalco FJ, Ryan PB et al (2018) Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes Metab 20(3):582\u2013589. \n                    https:\/\/doi.org\/10.1111\/dom.13115","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"4861_CR19","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","volume":"178","author":"HY Chang","year":"2018","unstructured":"Chang HY, Singh S, Mansour O, Baksh S, Alexander GC (2018) Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med 178(9):1190\u20131198. \n                    https:\/\/doi.org\/10.1001\/jamainternmed.2018.3034","journal-title":"JAMA Intern Med"},{"issue":"1","key":"4861_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.13477","volume":"21","author":"GK Dawwas","year":"2019","unstructured":"Dawwas GK, Smith SM, Park H (2019) Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Obes Metab 21(1):28\u201336. \n                    https:\/\/doi.org\/10.1111\/dom.13477","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"4861_CR21","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/dom.13647","volume":"21","author":"Jeff Y. Yang","year":"2019","unstructured":"Yang JY, Wang T, Pate V et al (2019) Sodium-glucose cotransporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers. Diabetes Obes Metab. \n                    https:\/\/doi.org\/10.1111\/dom.13647","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"14","key":"4861_CR22","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","volume":"137","author":"JA Udell","year":"2018","unstructured":"Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N (2018) Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation 137(14):1450\u20131459. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031227","journal-title":"Circulation"},{"key":"4861_CR23","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstrom H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365. \n                    https:\/\/doi.org\/10.1136\/bmj.k4365","journal-title":"BMJ"},{"issue":"4","key":"4861_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40264-015-0271-2","volume":"38","author":"K Juhlin","year":"2015","unstructured":"Juhlin K, Karimi G, Ander M et al (2015) Using VigiBase to identify substandard medicines: detection capacity and key prerequisites. Drug Saf 38(4):373\u2013382. \n                    https:\/\/doi.org\/10.1007\/s40264-015-0271-2","journal-title":"Drug Saf"},{"issue":"9","key":"4861_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A (2017) SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 5(9):680\u2013681. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30257-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"4861_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/aje\/kwi223","volume":"162","author":"RL Prentice","year":"2005","unstructured":"Prentice RL, Langer R, Stefanick ML et al (2005) Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women\u2019s Health Initiative clinical trial. Am J Epidemiol 162(5):404\u2013414. \n                    https:\/\/doi.org\/10.1093\/aje\/kwi223","journal-title":"Am J Epidemiol"},{"key":"4861_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jsbmb.2015.08.011","volume":"164","author":"Y Oda","year":"2016","unstructured":"Oda Y, Tu CL, Menendez A, Nguyen T, Bikle DD (2016) Vitamin D and calcium regulation of epidermal wound healing. J Steroid Biochem Mol Biol 164:379\u2013385. \n                    https:\/\/doi.org\/10.1016\/j.jsbmb.2015.08.011","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"4861_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12011-017-1056-5","volume":"181","author":"R Razzaghi","year":"2018","unstructured":"Razzaghi R, Pidar F, Momen-Heravi M, Bahmani F, Akbari H, Asemi Z (2018) Magnesium supplementation and the effects on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial. Biol Trace Elem Res 181(2):207\u2013215. \n                    https:\/\/doi.org\/10.1007\/s12011-017-1056-5","journal-title":"Biol Trace Elem Res"},{"issue":"4","key":"4861_CR29","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jdiacomp.2016.06.017","volume":"31","author":"R Razzaghi","year":"2017","unstructured":"Razzaghi R, Pourbagheri H, Momen-Heravi M et al (2017) The effects of vitamin D supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial. J Diabetes Complicat 31(4):766\u2013772. \n                    https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.06.017","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"4861_CR30","doi-asserted-by":"publisher","first-page":"e3100","DOI":"10.1002\/dmrr.3100","volume":"35","author":"E Kalaitzoglou","year":"2019","unstructured":"Kalaitzoglou E, Fowlkes JL, Popescu I, Thrailkill KM (2019) Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes Metab Res Rev 35(2):e3100. \n                    https:\/\/doi.org\/10.1002\/dmrr.3100","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"4861_CR31","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME Trial. Diabetes Care 41(1):e4\u2013e5. \n                    https:\/\/doi.org\/10.2337\/dc17-1551","journal-title":"Diabetes Care"},{"key":"4861_CR32","doi-asserted-by":"publisher","unstructured":"(2018) Ertugliflozin for type 2 diabetes. JAMA 319(23): 2434\u20132435. \n                    https:\/\/doi.org\/10.1001\/jama.2018.5840","DOI":"10.1001\/jama.2018.5840"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4861-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-4861-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4861-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:09:47Z","timestamp":1585786187000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-4861-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4861"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-4861-x","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"type":"print","value":"0012-186X"},{"type":"electronic","value":"1432-0428"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EJB received support from Bayer AG for his participation at an expert committee meeting. MM-S and IR-V declare no duality of interest associated with this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}